{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:00:07Z","timestamp":1780477207959,"version":"3.54.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer demonstrates heterogeneous clinical behavior, underscoring the need for reliable prognostic biomarkers. Semi-quantitative parameters derived from fluorine\u201118 fluorodeoxyglucose PET\/CT, including spleen maximum standardized uptake value (SUVmax) and spleen-to-liver SUVmax ratio (SLR), may reflect systemic inflammatory activity and predict outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the prognostic significance of baseline spleen SUVmax and SLR, compared with other PET\/computed tomography (CT)-derived parameters, in predicting disease-free survival (DFS) in nonmetastatic breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ninety-two female patients with pathologically confirmed invasive breast cancer underwent baseline fluorine\u201118 fluorodeoxyglucose PET\/CT before treatment. SUVmax values for primary tumor, spleen, and bone marrow were measured, and SLR and bone marrow-to-liver SUVmax ratios were calculated. Associations with clinicopathological features were analyzed using chi-square and ANOVA tests. DFS predictors were evaluated using Cox regression and Kaplan\u2013Meier analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Higher spleen SUVmax and SLR were significantly associated with larger tumor size, advanced stage, higher grade, hormone receptor negativity, and triple-negative subtype (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.05). Patients with progressive disease had higher spleen SUVmax (2.93\u2005\u00b1\u20050.50) and SLR (0.87\u2005\u00b1\u20050.06) than those with complete remission (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). In univariate Cox regression, SLR remained a strong predictor of DFS [hazard ratio\u2005=\u20056.12, 95% confidence interval (CI): 2.05\u201318.25,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.001]. In multivariate analysis including SLR, Ki-67, stage, nodal status, and molecular subtype, only SLR remained independently significant (hazard ratio\u2005=\u20056.12, 95% CI: 2.05\u201318.25,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.001). Patients with SLR greater than 0.7083 had significantly shorter mean survival (14.5 vs. 31.6 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline SLR is a strong prognostic marker in nonmetastatic breast cancer along with tumor SUVmax and spleen SUVmax, and may aid in risk stratification and treatment planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002144","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:00:19Z","timestamp":1774944019000},"page":"799-806","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pilot study: prognostic significance of semi-quantitative parameters in baseline fluorine\u201118 fluorodeoxyglucose PET\/computed tomography in nonmetastatic breast cancer patients"],"prefix":"10.1097","volume":"47","author":[{"given":"Nahla Dessoki","family":"Elsayed","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna Tarek","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasen Amin","family":"Abou Gabal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa Hamdy Ibrahim","family":"Azab","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kasr el Aini Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Salama","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"R1-20260603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","article-title":"Molecular classification of breast cancer.","volume":"27","author":"Tsang","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"R2-20260603","first-page":"100469","article-title":"The clinical behavior of different molecular subtypes of breast cancer.","volume":"29","author":"Mohammed","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"Suppl 1","key":"R3-20260603","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.21037\/tcr.2019.07.07","article-title":"Examining the evolving utility of 18F-FDG PET\/CT in breast cancer recurrence.","volume":"9","author":"Djassemi","year":"2020","journal-title":"Transl Cancer Res"},{"key":"R4-20260603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40336-021-00426-z","article-title":"Breast cancer: initial workup and staging with FDG PET\/CT.","volume":"9","author":"Groheux","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"R5-20260603","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/bjr\/tqad015","article-title":"Elevated splenic 18F-FDG PET\/CT activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.","volume":"97","author":"Wang","year":"2024","journal-title":"Br J Radiol"},{"key":"R6-20260603","doi-asserted-by":"crossref","first-page":"1004351","DOI":"10.3389\/fimmu.2022.1004351","article-title":"Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"R7-20260603","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7150\/thno.35989","article-title":"Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG PET.","volume":"10","author":"Schwenck","year":"2020","journal-title":"Theranostics"},{"key":"R8-20260603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.23736\/S1824-4785.17.02810-2","article-title":"Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma.","volume":"62","author":"Chiacchio","year":"2018","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R9-20260603","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1007\/s00259-021-05322-2","article-title":"Total metabolic tumor volume and spleen metabolism on baseline 18F-FDG PET\/CT as independent prognostic biomarkers of recurrence in resected breast cancer.","volume":"48","author":"Seban","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20260603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MEG.0000000000001018","article-title":"18F-FDG uptake of bone marrow on PET\/CT can predict prognosis in patients with colorectal cancer after curative surgical resection.","volume":"30","author":"Lee","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R11-20260603","first-page":"345","article-title":"Tumor and nodal distribution in breast cancer: a multicenter study.","volume":"49","author":"Osman","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"R12-20260603","doi-asserted-by":"crossref","first-page":"e0208861","DOI":"10.1371\/journal.pone.0208861","article-title":"Clinical utility of FDG uptake within reticuloendothelial system on 18F-FDG PET\/CT for prediction of tumor recurrence in breast cancer.","volume":"13","author":"Bang","year":"2018","journal-title":"PLoS One"},{"key":"R13-20260603","first-page":"11","article-title":"Association of 18F-FDG PET\/CT textural features with immunohistochemical characteristics in invasive ductal breast cancer.","volume":"41","author":"Onner","year":"2022","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"R14-20260603","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11547-025-01961-9","article-title":"Baseline 18F-FDG PET\/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters.","volume":"130","author":"Taralli","year":"2025","journal-title":"Radiol Med"},{"key":"R15-20260603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40644-021-00424-4","article-title":"Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism characteristics measured using FDG PET\/CT.","volume":"21","author":"Kwon","year":"2021","journal-title":"Cancer Imaging"},{"key":"R16-20260603","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/MNM.0000000000002039","article-title":"Utilization of 18F-FDG PET\/CT in evaluating systemic immune response in malignancies: emphasis on spleen and bone marrow metabolism.","volume":"46","author":"Cajamarca-Baron","year":"2025","journal-title":"Nucl Med Commun"},{"key":"R17-20260603","first-page":"300","article-title":"Enhanced glucose metabolism in inflammatory cells contributes to increased FDG uptake on PET\/CT.","volume":"39","author":"Zhou","year":"2018","journal-title":"Nucl Med Commun"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:00:16Z","timestamp":1780473616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002144","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2026-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}